Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Deferred Taxes (2016 - 2025)

Historic Deferred Taxes for Anika Therapeutics (ANIK) over the last 15 years, with Q3 2025 value amounting to $3000.0.

  • Anika Therapeutics' Deferred Taxes rose 10163.04% to $3000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $252000.0, marking a year-over-year increase of 11386.9%. This contributed to the annual value of $260000.0 for FY2024, which is 10410.94% up from last year.
  • Per Anika Therapeutics' latest filing, its Deferred Taxes stood at $3000.0 for Q3 2025, which was up 10163.04% from -$3000.0 recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Deferred Taxes registered a high of $2.4 million during Q2 2021, and its lowest value of -$2.8 million during Q4 2021.
  • Moreover, its 5-year median value for Deferred Taxes was -$273000.0 (2022), whereas its average is -$688684.2.
  • Data for Anika Therapeutics' Deferred Taxes shows a peak YoY increase of 26183.94% (in 2021) and a maximum YoY decrease of 105518.67% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Anika Therapeutics' Deferred Taxes stood at -$2.8 million in 2021, then soared by 36.1% to -$1.8 million in 2022, then fell by 3.6% to -$1.8 million in 2023, then surged by 112.7% to $234000.0 in 2024, then crashed by 98.72% to $3000.0 in 2025.
  • Its last three reported values are $3000.0 in Q3 2025, -$3000.0 for Q2 2025, and $18000.0 during Q1 2025.